These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
882 related articles for article (PubMed ID: 15377287)
1. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. Maher L; Chant K; Jalaludin B; Sargent P J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287 [TBL] [Abstract][Full Text] [Related]
2. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users. Devi KhS; Brajachand N; Singh HL; Singh YM J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404 [TBL] [Abstract][Full Text] [Related]
3. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555 [TBL] [Abstract][Full Text] [Related]
4. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050 [TBL] [Abstract][Full Text] [Related]
5. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations. Kemp R; Miller J; Lungley S; Baker M N Z Med J; 1998 Feb; 111(1060):50-3. PubMed ID: 9539916 [TBL] [Abstract][Full Text] [Related]
6. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Rahimi-Movaghar A; Razaghi EM; Sahimi-Izadian E; Amin-Esmaeili M Int J Infect Dis; 2010 Jan; 14(1):e28-33. PubMed ID: 19464218 [TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis C prevalence and risk behavior of injecting drug users in Sydney: a continuing concern. Habib SE; Lovejoy FH; Aspin C Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):823-34. PubMed ID: 12041560 [TBL] [Abstract][Full Text] [Related]
9. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning. Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463 [TBL] [Abstract][Full Text] [Related]
10. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671 [TBL] [Abstract][Full Text] [Related]
11. Higher HCV antibody prevalence among Indigenous clients of needle and syringe programs. Ward J; Topp L; Iversen J; Wand H; Akre S; Kaldor J; Maher L Aust N Z J Public Health; 2011 Oct; 35(5):421-6. PubMed ID: 21973248 [TBL] [Abstract][Full Text] [Related]
12. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390 [TBL] [Abstract][Full Text] [Related]
13. Irish injecting drug users and hepatitis C: the importance of the social context of injecting. Smyth BP; Barry J; Keenan E Int J Epidemiol; 2005 Feb; 34(1):166-72. PubMed ID: 15513970 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors. Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme. Chetwynd J; Brunton C; Blank M; Plumridge E; Baldwin D N Z Med J; 1995 Sep; 108(1007):364-6. PubMed ID: 7566775 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia. White B; Day C; Degenhardt L; Kinner S; Fry C; Bruno R; Johnston J Drug Alcohol Depend; 2006 Jul; 83(3):210-7. PubMed ID: 16343810 [TBL] [Abstract][Full Text] [Related]
17. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia. Vicknasingam B; Narayanan S; Navaratnam V Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. Judd A; Hutchinson S; Wadd S; Hickman M; Taylor A; Jones S; Parry JV; Cameron S; Rhodes T; Ahmed S; Bird S; Fox R; Renton A; Stimson GV; Goldberg D J Viral Hepat; 2005 Nov; 12(6):655-62. PubMed ID: 16255768 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of hepatitis B and C among HIV positive patients in Georgia and its associated risk factors. Badridze N; Chkhartishvili N; Abutidze A; Gatserelia L; Sharvadze L Georgian Med News; 2008 Dec; (165):54-60. PubMed ID: 19124918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]